Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

Core Insights - Metagenomi Therapeutics, Inc. is an in vivo genome editing company focused on creating curative genetic medicines using proprietary technologies [3] - The company will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference on March 2, 2026 [1][2] Company Overview - Metagenomi Therapeutics was founded on the science of metagenomics, aiming to develop novel editing tools for correcting genetic mutations in the human genome [3] - The company is concentrating on high-value programs with well-understood biology and clear clinical development pathways [3] Product Development - The lead program, MGX-001, targets hemophilia A and has shown a preclinical profile that may compete with best-in-class treatments, offering potential lifelong protection from bleeding events [4] - The company is also exploring other conditions related to secreted protein deficiencies and cardiometabolic diseases using its genome integration system [4]